Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

HER-2 DNA AutoVac therapeutic vaccine safe and immunogenic in breast cancer patients

Dec. 19, 2002

Modified dosing schedule of apolizumab allows higher doses in CLL and ALL

Dec. 19, 2002

Trifunctional bispecific antibody shows potential for B-cell lymphoma

Dec. 18, 2002

TP-38 demonstrates antitumor activity in glioblastoma

Dec. 17, 2002

Potential use of CC-5013 in the treatment of hematological malignancies

Dec. 17, 2002

Disappointing phase III preliminary results for CeaVac in colorectal cancer

Dec. 16, 2002

IDEC-114 reported safe and effective in refractory follicular lymphoma

Dec. 16, 2002

Minimal toxicity reported for SGN-30 in Hodgkin's disease and lymphoma

Dec. 13, 2002

MDX-060 has marked antitumor activity in CD30+ lymphoma-bearing mice

Dec. 11, 2002

Vasogen reports preliminary results from pilot study in CLL

Dec. 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026